The age-related eye disease study (AREDS): Design implications AREDS report no. 1

A. S. Lindblad, A. Kassoff, S. Kieval, M. Mehu, J. Buehler, M. Eglow, F. Kaufman, R. R. Margherio, M. S. Cox, B. Garretson, T. Hassan, A. Ruby, M. T. Trese, J. C. Werner, G. A. Williams, V. Regan, P. Manatrey, K. Cumming, M. Zajechowski, R. FalkP. Streasick, L. Szydlowski, R. F. Dreyer, C. Ma, C. Beardsley, H. Crider, Jr Capone A., T. M. Aaberg, D. Martin, D. Saperstein, Jr Sternberg P., L. Curtis, B. Stribling, J. Gilman, B. Myles, R. Swords, D. H. Orth, T. P. Flood, J. Civantos, S. DeBustros, K. H. Packo, C. MacLeod, C. Morrison, D. A. Bryant, D. Doherty, S. Sandoval, J. M. Seddon, M. K. Pinnolis, D. A. Jones-Devonish, V. D. Crouse, K. K. Snow, C. Evans, N. Davis, C. Callahan, D. Walsh, J. Dubois, I. Burton, F. L. Ferris, E. Y. Chew, K. Csaky, S. A. McCarthy, K. H. Dabas, L. Goodman, Ja Kim Young Ja Kim, P. Lopez, R. Mercer, L. M. Ayres, T. LaRean, A. Randall, M. Chicca, P. F. Ciatto, E. Kuehl, I. Kivitz, D. Koutsandreas, T. R. Friberg, A. Eller, M. B. Gorin, J. Alexander, B. Mack, S. B. Bressler, N. M. Bressler, G. Cassel, M. Goldberg, J. A. Haller, L. Ratner, A. P. Schachat, S. H. Sherman, J. S. Sunness, S. Schenning, C. Sackett, D. Cain, D. Emmert, T. George, S. Wheeler, M. J. Elman, R. Ballinger, A. Betancourt, D. Glasser, J. Lammlein

Research output: Contribution to journalArticlepeer-review

319 Scopus citations


The Age-Related Eye Disease Study (AREDS) was initially conceived as a long-term multicenter, prospective study of the clinical course of age- related macular degeneration (AMD) and age-related cataract. Data on progression rates and risk factors from the study will increase understanding of the clinical course of both conditions, generate hypotheses about etiology, and aid in the design of clinical trials of potential interventions. In addition to collecting natural history data, AREDS includes a clinical trial of high-dose vitamin and mineral supplements for AMD and a clinical trial of high-dose vitamin supplements for cataract. The clinical trials were initiated largely because of the widespread public use in the United States of commercially available pharmacologic doses of vitamins and minerals to treat these two eye conditions and the absence of definitive studies on the safety and efficacy of their use. Important design issues for the clinical trials include: defining cataract and AMD, estimating event rates, determining the type and dosage of vitamins and minerals to be tested for each condition, and identifying the parameters necessary for monitoring safety and efficacy. This paper describes the AREDS design, including the study rationale and operational structure, and the approach adopted to combine, for two diseases, clinical trials with a natural history study.

Original languageEnglish (US)
Pages (from-to)573-600
Number of pages28
JournalControlled clinical trials
Issue number6
StatePublished - Dec 1999
Externally publishedYes


  • Age-related macular degeneration
  • Antioxidants
  • Beta-carotene
  • Cataract
  • Clinical course
  • Clinical trial
  • Vitamin C
  • Vitamin E
  • Zinc

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'The age-related eye disease study (AREDS): Design implications AREDS report no. 1'. Together they form a unique fingerprint.

Cite this